{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-089095","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2024-10-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.532587+00:00","generated_at":"2026-05-30T12:32:52.177737+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Kyverna Therapeutics appoints cell therapy veteran Mert Aktar to board","bullets":["Appointed Mert Aktar as Class III director, effective Oct 20, 2024; joins Audit and Science & Technology Committees.","Aktar currently CEO of Receptive Bio; previously SVP Global Head of Corp Dev at Kite Pharma; over 20 years biopharma experience.","As non-employee director, receives $40k/yr cash, $10k Audit, $7.5k SciTech committee fees; plus $350k option grant vesting monthly over 3 years.","Appointment adds cell therapy and corporate development expertise as Kyverna advances KYV-101 in autoimmune disease trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-089095","json":"https://secwatch.observer/filing/0001213900-24-089095.json","markdown":"https://secwatch.observer/filing/0001213900-24-089095.md","text":"https://secwatch.observer/filing/0001213900-24-089095.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000121390024089095/0001213900-24-089095-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000121390024089095/ea0218096-8k_kyverna.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T12:32:52.177737+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c0d9477fbc","claim":"Mert Aktar was appointed as Class III director at Kyverna Therapeutics, Inc..","evidence_excerpt":"On October 20, 2024, the board of directors (the \"Board\") of Kyverna Therapeutics, Inc. (the \"Company\") appointed Mert Aktar as a Class III director of the Company, effective October 20, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1994702/000121390024089095/0001213900-24-089095-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}